-
Mashup Score: 2Panel Shares Management Considerations for Patients Undergoing NSCLC Treatment | Docwire News - 7 day(s) ago
The panel discusses how to manage and counsel patients about adverse events and toxicities related to treatment for NSCLC, as well as the importance of a multidisciplinary team.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News - 7 day(s) ago
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How do socioeconomic factors affect care and surgical outcomes for veterans with NSCLC? 📰 A new study by a team from @WUSTL provided insights and key action items. ➡️ Learn more: https://t.co/yULaGnbLvZ #lcsm #LungCancer #NSCLC https://t.co/4PAh7ITbOL
-
-
Mashup Score: 3Lung Cancer Genetics Study Launched by LCRF, Advocacy Organizations, 23andMe | Docwire News - 8 day(s) ago
Twenty lung cancer advocacy organizations will be collaborating with the Lung Cancer Research Foundation (LCRF) and 23andMe Holding Co. to conduct the Lung Cancer Genetics Study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🧬 The Lung Cancer Genetics Study, a collaboration among @lcrf_org, @23andMe & lung cancer advocacy organizations, aims to build a “comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer." ➡️ Read more: https://t.co/GjzlIbxeVa #lcsm https://t.co/1WpFCxnGz5
-
-
Mashup Score: 2
Roselle De Guzman, MD, discusses why it’s critical to raise awareness about how indoor air pollutant exposure can impact lung cancer risk.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 ICYMI: @DrRoselleDG joined us at #WCLC24 to share insights from her plenary presentation titled "Unmasking Indoor Pollutants and Lung Cancer Risk.” ⭐ Don't miss this interview! ➡️ Watch now: https://t.co/9wxexBwFBc #lcsm #lungcancer https://t.co/MHzgpxDarm
-
-
Mashup Score: 7FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for ES-SCLC | Docwire News - 9 day(s) ago
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab govitecan-hziy (Trodelvy®) for extensive-stage small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGULATORY UPDATE: The US FDA has granted Breakthrough Therapy Designation to sacituzumab govitecan as a treatment for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy. ➡️ Learn more: https://t.co/OWQtoXUtD2 #lcsm #SCLC https://t.co/5EWrVNTg5e
-
-
Mashup Score: 3FDA Issues Complete Response Letter for Subcutaneous Amivantamab in NSCLC | Docwire News - 9 day(s) ago
The Complete Response Letter “is related to observations as part of a standard pre-approval inspection at a manufacturing facility,” according to Johnson & Johnson officials.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📄 The US FDA has issued a Complete Response Letter for the Biologics License Application for subcutaneous amivantamab in NSCLC, according to Johnson & Johnson officials. ➡️ Learn more about the letter and the next steps: https://t.co/xs6BiSv8x2 #lcsm #NSCLC #LungCancer https://t.co/JtUVhh3QXb
-
-
Mashup Score: 2Implementing the Rural Appalachian Lung Cancer Screening Initiative: Dr. Gieske Shares Insights | Docwire News - 10 day(s) ago
Michael R. Gieske, MD, of the St. Elizabeth Cancer Center, discusses the Rural Appalachian Lung Cancer Screening Initiative at IASLC 2024 World Conference on Lung Cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Don't miss this interview with @mrgieske, who joined us to discuss his work exploring community perceptions & practices to inform lung cancer screening interventions. ➡️ Watch: https://t.co/Lj7LQCcepq #lcsm #LungCancer #NSCLC #SCLC #WCLC24 https://t.co/n7i3DOPfMm
-
-
Mashup Score: 3FDA Approves Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC | Docwire News - 10 day(s) ago
The U.S. Food and Drug Administration has approved ensartinib (Ensacove) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGULATORY UPDATE: The FDA has approved ensartinib for adults with ALK-positive locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor. ➡️ Learn more: https://t.co/EZ8n6O4ckc #NSCLC #lcsm #ALK https://t.co/FsawLzXPU9
-
-
Mashup Score: 2Mark Your Calendar: Application Window Opens for LUNGevity Research Awards on January 13, 2025 - 11 day(s) ago
Research is central to improving outcomes of people diagnosed with and living with lung cancer. In 2025, LUNGevity is proud to continue our commitment to developing and sustaining a vibrant workforce in thoracic oncology.
Source: www.linkedin.comCategories: General Medicine News, Partners & KOLsTweet-
RT @LUNGevity: Mark Your Calendar: Application Window Opens for LUNGevity Research Awards on January 13, 2025! https://t.co/MoUiX8N5ou
-
-
Mashup Score: 4
The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGUALTORY UPDATE: The US Food and Drug Administration has approved durvalumab for adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ➡️ Learn more: https://t.co/xv5SVGZG9j #SCLC #LCSM https://t.co/dj7fwVAB2F
-
🫁 What are the key management considerations when it comes to NSCLC? 💡 Don't miss this roundtable discussion on the topic, which features @DasMillie11, @LealTiciana, @DoctorDietrich, and Kent Shih, MD. ➡️ Watch now: https://t.co/A0tPIMT019 #lcsm #NSCLC #lungcancer https://t.co/W55zW0pRBp